RecruitingNCT06764459

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

20 participants

Start Date

Mar 15, 2023

Study Type

OBSERVATIONAL

Conditions

Myeloid Leukemia, Acute

Summary

This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is analyzing the genetic makeup of acute myeloid leukemia (AML) tumors in patients with a FLT3 gene mutation and tracking how the cancer changes over time in response to treatment — a process called clonal evolution. **You may be eligible if...** - You have acute myeloid leukemia with a confirmed FLT3 gene mutation **You may NOT be eligible if...** - Your AML has already responded successfully to therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.